The public body responsible for providing guidance and advice for England and Wales, the National Institute for Health and Care Excellence (NICE), is now clarifying an earlier statement, which suggested it did not recommend Leo Pharma’s atopic eczema treatment Adtralza (tralokinumab).
”It has come to our attention that the note to media issues on 8 April 2022 in relation to this appraisal may have created the inaccurate impression that final guidance had been issues by NICE,” the authority writes in a statement, emphasizing that Leo Pharma has been able to comment on the indicative rejection until May 4.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Long wait for IVDR implementation is over, putting an end to pandemic "wild west"
After prolonged debates on potential bottlenecking and supply issues, the EU’s long-awaited In Vitro Diagnostic Medical Devices Regulation comes into force on May 26.
GN purchase story is very speculative, says analyst
Competition rules could block a purchase of GN Store Nord and subsequent divestment of GN Hearing, says a Sydbank analyst on the speculative story that this might be underway.
Bavarian Nordic upgrades guidance following vaccine contract
Bavarian has been the center of attention in recent days due to its monkeypox vaccine, and the company has now secured a vaccine contract with another undisclosed country. Consequently, Bavarian has raised its expectations for the full year.
Novo Nordisk invests additional millions of dollars in new manufacturing facilities
Novo Nordisk’s DKK 17bn (USD 2.4bn) investment into upgrading and building new facilities in Kalundborg last year has now been followed by a DKK 1bn (USD 143.8m) investment in the same location.
US to start using Bavarian vaccine stockpile
In an attempt to contain a monkeypox outbreak, US authorities will start offering certain people Bavarian Nordic-developed Jynneos vaccinations against the infectious disease.
2 Sales Representatives and Product Specialists 
Clinical Trial Administrator 
Industrial Designer- Design Engineer 
CMO Operations Specialist - screening & selection of CMO/CDMO’s 
Biomarker Operations Lead 
Chemist for Incoming Materials in QC Department 
Account Manager 
Clinical Trial Manager 
Director Global Engineering 
Nordic Medical Affairs Manager 
Senior Project Manager (GMP - Life Science) 
IRT Manager, Clinical Drug Supply 
Communications Consultant 
Clinical Trial Manager for development of in vitro diagnostics 
Client Talent Acquisition Specialist 
Key Account Manager, Europe and Asia 
Senior Chemical Safety Advisor